Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential CCRT plus surgery vs surgery alone in non-CCR ESCC after neoadjuvant chemoimmunotherapy
ChiCTR2500109910Phase 3Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Sep 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tislelizumab, paclitaxel and carboplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Sichuan Cancer Hospital. Primary endpoint: Pathological complete response rate (pCR). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
tislelizumabpaclitaxelcarboplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500109910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109910.